Aurobindo Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Aurobindo Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 13.6% bzw. 8.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.1% betragen.

Wichtige Informationen

13.6%

Wachstumsrate der Gewinne

13.73%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	14.9%
Wachstumsrate der Einnahmen	8.1%
Zukünftige Eigenkapitalrendite	11.12%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 May 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 10

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Recent updates

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

May 04

Aurobindo Pharma Limited (NSE:AUROPHARMA) Doing What It Can To Lift Shares

Mar 28

If EPS Growth Is Important To You, Aurobindo Pharma (NSE:AUROPHARMA) Presents An Opportunity

Feb 26

Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 10

Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Jan 24

Penicillin G Ramp-Up And Biosimilar Breakthroughs To Propel Revenue Growth And Boost Net Margins

Jan 05 Strategic focus on new product launches and U.S. pricing stability can drive revenue growth while improving EBITDA margins.

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Gewinn- und Umsatzwachstumsprognosen

NSEI:AUROPHARMA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2028	384,669	48,527	44,870	N/A	1
3/31/2027	371,714	47,692	40,561	N/A	22
3/31/2026	347,799	44,670	35,013	N/A	26
3/31/2025	315,478	36,519	30,877	N/A	23
12/31/2024	309,218	34,912	N/A	N/A	N/A
9/30/2024	302,950	35,816	-7,760	15,867	N/A
6/30/2024	297,184	35,214	N/A	N/A	N/A
3/31/2024	290,019	31,730	-11,270	24,345	N/A
12/31/2023	278,947	27,705	N/A	N/A	N/A
9/30/2023	269,500	23,254	-16,080	19,946	N/A
6/30/2023	254,700	19,777	N/A	N/A	N/A
3/31/2023	248,554	19,275	-3,336	23,868	N/A
12/31/2022	241,918	19,977	N/A	N/A	N/A
9/30/2022	237,869	21,112	28,497	52,208	N/A
6/30/2022	239,894	23,987	N/A	N/A	N/A
3/31/2022	234,555	26,482	23,118	50,165	N/A
12/31/2021	236,476	28,676	N/A	N/A	N/A
9/30/2021	240,103	52,109	1,278	28,769	N/A
6/30/2021	245,518	53,217	N/A	N/A	N/A
3/31/2021	247,746	53,348	14,552	33,291	N/A
12/31/2020	249,316	53,831	N/A	N/A	N/A
9/30/2020	244,617	31,421	29,266	42,542	N/A
6/30/2020	235,787	29,757	N/A	N/A	N/A
3/31/2020	230,985	28,451	29,502	43,813	N/A
12/31/2019	222,323	25,666	N/A	N/A	N/A
9/30/2019	216,070	25,733	N/A	N/A	N/A
6/30/2019	207,579	25,449	N/A	N/A	N/A
3/31/2019	195,636	23,647	919	16,510	N/A
12/31/2018	183,834	23,078	N/A	N/A	N/A
9/30/2018	174,246	21,906	N/A	N/A	N/A
6/30/2018	171,091	23,603	N/A	N/A	N/A
3/31/2018	164,630	24,232	N/A	19,545	N/A
12/31/2017	159,381	24,271	N/A	N/A	N/A
9/30/2017	154,903	24,107	N/A	N/A	N/A
6/30/2017	148,279	22,352	N/A	N/A	N/A
3/31/2017	149,334	23,017	N/A	32,786	N/A
12/31/2016	151,565	22,809	N/A	N/A	N/A
9/30/2016	147,559	22,466	N/A	N/A	N/A
6/30/2016	143,446	20,945	N/A	N/A	N/A
3/31/2016	138,162	20,251	N/A	14,198	N/A
12/31/2015	133,249	18,230	N/A	N/A	N/A
9/30/2015	129,956	16,724	N/A	N/A	N/A
6/30/2015	125,433	15,928	N/A	N/A	N/A
3/31/2015	121,340	15,758	N/A	12,368	N/A
12/31/2014	112,825	16,738	N/A	N/A	N/A
9/30/2014	102,756	17,069	N/A	N/A	N/A
6/30/2014	93,109	15,697	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AUROPHARMADas prognostizierte Gewinnwachstum (13.6% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: AUROPHARMADie Erträge des Unternehmens (13.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (15.4% pro Jahr).

Hohe Wachstumserträge: AUROPHARMADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: AUROPHARMADie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: AUROPHARMADie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AUROPHARMADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.1%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/05/21 17:12
Aktienkurs zum Tagesende	2025/05/21 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Aurobindo Pharma Limited wird von 55 Analysten beobachtet. 26 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Meeta Shetty	Asian Markets Securities Private Limited
Kamlesh Kotak	Asian Markets Securities Private Limited
Harith Ahamed	Avendus Spark

Aurobindo Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Recent updates

Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation

Aurobindo Pharma Limited to Report Q4, 2025 Results on May 26, 2025

Esperion Reaches Settlement Agreement with Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) Prior to April 19, 2040

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited (NSE:AUROPHARMA) Doing What It Can To Lift Shares

If EPS Growth Is Important To You, Aurobindo Pharma (NSE:AUROPHARMA) Presents An Opportunity

Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aurobindo Pharma Limited Announced the Details of Action Initiated by U.S. Food and Drug Administration (US FDA), USA

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited to Report Q3, 2025 Results on Feb 06, 2025

Penicillin G Ramp-Up And Biosimilar Breakthroughs To Propel Revenue Growth And Boost Net Margins

Less than half of directors are independent

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings released: EPS: ₹14.00 (vs ₹12.83 in 2Q 2024)

Aurobindo Pharma Limited to Report Q2, 2025 Results on Nov 09, 2024

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind